BCR-ABL + acute myeloid leukemia: are we always dealing with a high-risk disease?
| Autor: | Philipp Hemmati, Nina Rosa Neuendorff, Jörg Westermann, Jana Ihlow, Renate Arnold, Bernd Dörken, Carsten Müller-Tidow |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Oncology
medicine.medical_specialty Myeloid business.industry Myeloid leukemia Hematology Disease medicine.disease World health 03 medical and health sciences Leukemia 0302 clinical medicine medicine.anatomical_structure hemic and lymphatic diseases 030220 oncology & carcinogenesis Internal medicine Commentary medicine In patient Differential diagnosis business neoplasms 030215 immunology |
| Zdroj: | Blood Advances. 2:1409-1411 |
| ISSN: | 2473-9537 2473-9529 |
| DOI: | 10.1182/bloodadvances.2018015594 |
| Popis: | TO THE EDITOR: BCR-ABL + acute myeloid leukemia (AML) has recently been listed in the 2016 revised World Health Organization (WHO) classification of myeloid malignancies as a provisional entity.[1][1] BCR-ABL + AML comprises a group of de novo AML in patients without evidence of an underlying |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|